BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

823 related articles for article (PubMed ID: 18199717)

  • 21. Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma.
    Tischoff I; Hengge UR; Vieth M; Ell C; Stolte M; Weber A; Schmidt WE; Tannapfel A
    Gut; 2007 Aug; 56(8):1047-53. PubMed ID: 17376806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus.
    Clément G; Braunschweig R; Pasquier N; Bosman FT; Benhattar J
    Oncogene; 2006 May; 25(21):3084-92. PubMed ID: 16407829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Fontolliet C; Bosman FT; Benhattar J
    Gastroenterology; 2002 Apr; 122(4):1113-21. PubMed ID: 11910361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular Evolution of Metaplasia to Adenocarcinoma in the Esophagus.
    Grady WM; Yu M
    Dig Dis Sci; 2018 Aug; 63(8):2059-2069. PubMed ID: 29766388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
    Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
    Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cellular origins and molecular mechanisms of Barrett's esophagus and esophageal adenocarcinoma.
    Fang Y; Chen X; Bajpai M; Verma A; Das KM; Souza RF; Garman KS; Donohoe CL; O'Farrell NJ; Reynolds JV; Dvorak K
    Ann N Y Acad Sci; 2013 Oct; 1300():187-199. PubMed ID: 24117642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aberrant methylation of the Ras-related associated with diabetes gene in human primary esophageal cancer.
    Jin Z; Feng X; Jian Q; Cheng Y; Gao Y; Zhang X; Wang L; Zhang Y; Huang W; Fan X; Chen S; Yu H; Zhao Z; Dong M; Liu J; Mori Y; Meltzer SJ
    Anticancer Res; 2013 Nov; 33(11):5199-203. PubMed ID: 24222170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma.
    Peng DF; Razvi M; Chen H; Washington K; Roessner A; Schneider-Stock R; El-Rifai W
    Gut; 2009 Jan; 58(1):5-15. PubMed ID: 18664505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma.
    Wu W; Bhagat TD; Yang X; Song JH; Cheng Y; Agarwal R; Abraham JM; Ibrahim S; Bartenstein M; Hussain Z; Suzuki M; Yu Y; Chen W; Eng C; Greally J; Verma A; Meltzer SJ
    Gastroenterology; 2013 May; 144(5):956-966.e4. PubMed ID: 23333711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarker identification and trans-regulatory network analyses in esophageal adenocarcinoma and Barrett's esophagus.
    Lv J; Guo L; Wang JH; Yan YZ; Zhang J; Wang YY; Yu Y; Huang YF; Zhao HP
    World J Gastroenterol; 2019 Jan; 25(2):233-244. PubMed ID: 30670912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
    Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
    Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic alteration of the Wnt inhibitory factor-1 promoter occurs early in the carcinogenesis of Barrett's esophagus.
    Clément G; Guilleret I; He B; Yagui-Beltrán A; Lin YC; You L; Xu Z; Shi Y; Okamoto J; Benhattar J; Jablons D
    Cancer Sci; 2008 Jan; 99(1):46-53. PubMed ID: 18005197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma.
    Smith E; De Young NJ; Pavey SJ; Hayward NK; Nancarrow DJ; Whiteman DC; Smithers BM; Ruszkiewicz AR; Clouston AD; Gotley DC; Devitt PG; Jamieson GG; Drew PA
    Mol Cancer; 2008 Oct; 7():75. PubMed ID: 18831746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cdx2 expression and its promoter methylation during metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus.
    Makita K; Kitazawa R; Semba S; Fujiishi K; Nakagawa M; Haraguchi R; Kitazawa S
    World J Gastroenterol; 2013 Jan; 19(4):536-41. PubMed ID: 23382633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis.
    Wang S; Zhan M; Yin J; Abraham JM; Mori Y; Sato F; Xu Y; Olaru A; Berki AT; Li H; Schulmann K; Kan T; Hamilton JP; Paun B; Yu MM; Jin Z; Cheng Y; Ito T; Mantzur C; Greenwald BD; Meltzer SJ
    Oncogene; 2006 Jun; 25(23):3346-56. PubMed ID: 16449976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Whole genome expression array profiling highlights differences in mucosal defense genes in Barrett's esophagus and esophageal adenocarcinoma.
    Nancarrow DJ; Clouston AD; Smithers BM; Gotley DC; Drew PA; Watson DI; Tyagi S; Hayward NK; Whiteman DC; ;
    PLoS One; 2011; 6(7):e22513. PubMed ID: 21829465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression.
    Kuester D; Dar AA; Moskaluk CC; Krueger S; Meyer F; Hartig R; Stolte M; Malfertheiner P; Lippert H; Roessner A; El-Rifai W; Schneider-Stock R
    Neoplasia; 2007 Mar; 9(3):236-45. PubMed ID: 17401463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In-depth characterization of the Wnt-signaling/β-catenin pathway in an in vitro model of Barrett's sequence.
    Götzel K; Chemnitzer O; Maurer L; Dietrich A; Eichfeld U; Lyros O; Moulla Y; Niebisch S; Mehdorn M; Jansen-Winkeln B; Vieth M; Hoffmeister A; Gockel I; Thieme R
    BMC Gastroenterol; 2019 Mar; 19(1):38. PubMed ID: 30841855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma.
    Kaz AM; Grady WM; Stachler MD; Bass AJ
    Gastroenterol Clin North Am; 2015 Jun; 44(2):473-89. PubMed ID: 26021206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subtypes of Barrett's oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis.
    Yu M; Maden SK; Stachler M; Kaz AM; Ayers J; Guo Y; Carter KT; Willbanks A; Heinzerling TJ; O'Leary RM; Xu X; Bass A; Chandar AK; Chak A; Elliott R; Willis JE; Markowitz SD; Grady WM
    Gut; 2019 Mar; 68(3):389-399. PubMed ID: 29884612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.